{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T09:01:33Z","timestamp":1769158893061,"version":"3.49.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Zhejiang Province Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007194","name":"Wenzhou Municipal Science and Technology Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007194","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.bbrc.2022.03.147","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T11:32:58Z","timestamp":1648553578000},"page":"31-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["AT7519 against lung cancer via the IL6\/STAT3 signaling pathway"],"prefix":"10.1016","volume":"609","author":[{"given":"Feng","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanyun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianru","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhucheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luyao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shichong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lehe","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengguang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangxing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jifa","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1102-3403","authenticated-orcid":false,"given":"Xiaoying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2022.03.147_bib1","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"Ca-A Cancer Journal for Clinicians"},{"key":"10.1016\/j.bbrc.2022.03.147_bib2","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1111\/jcmm.14844","article-title":"Down-regulation of MTHFD2 inhibits NSCLC progression by suppressing cycle-related genes","volume":"24","author":"Yu","year":"2020","journal-title":"J.\u00a0Cell Mol. Med."},{"key":"10.1016\/j.bbrc.2022.03.147_bib3","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1001\/jamaoncol.2016.5829","article-title":"Association of delayed adjuvant chemotherapy with survival after lung cancer surgery","volume":"3","author":"Salazar","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.bbrc.2022.03.147_bib4","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.bbrc.2022.03.147_bib5","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nrc3818","article-title":"Revisiting STAT3 signalling in cancer: new and unexpected biological functions","volume":"14","author":"Yu","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2022.03.147_bib6","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2022.03.147_bib7","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: a leading role for STAT3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2022.03.147_bib8","doi-asserted-by":"crossref","first-page":"6703","DOI":"10.1158\/1078-0432.CCR-13-0621","article-title":"HAb18G\/CD147 promotes pSTAT3-mediated pancreatic cancer development via CD44s","volume":"19","author":"Li","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2022.03.147_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13046-018-1015-9","article-title":"Rhein sensitizes human pancreatic cancer cells to EGFR inhibitors by inhibiting STAT3 pathway","volume":"38","author":"Yang","year":"2019","journal-title":"J.\u00a0Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2022.03.147_bib10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cytogfr.2019.10.005","article-title":"Novel activators and small-molecule inhibitors of STAT3 in cancer","volume":"49","author":"Yang","year":"2019","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.bbrc.2022.03.147_bib11","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.7150\/thno.23046","article-title":"PIAS3-mediated feedback loops promote chronic colitis-associated malignant transformation","volume":"8","author":"Ma","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.bbrc.2022.03.147_bib12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.tips.2015.10.001","article-title":"Feedback activation of STAT3 as a cancer drug-resistance mechanism","volume":"37","author":"Zhao","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bbrc.2022.03.147_bib13","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1038\/s41388-020-1271-y","article-title":"Feedback activation of EGFR is the main cause for STAT3 inhibition-irresponsiveness in pancreatic cancer cells","volume":"39","author":"Zhao","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2022.03.147_bib14","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.1021\/jm800382h","article-title":"Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design","volume":"51","author":"Wyatt","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.bbrc.2022.03.147_bib15","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/mi.2013.102","article-title":"Downregulation of Mcl-1 has anti-inflammatory pro-resolution effects and enhances bacterial clearance from the lung","volume":"7","author":"Lucas","year":"2014","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.bbrc.2022.03.147_bib16","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1158\/1535-7163.MCT-08-0890","article-title":"Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines","volume":"8","author":"Squires","year":"2009","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.bbrc.2022.03.147_bib17","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41416-020-01135-6","article-title":"Acetyl-bufalin shows potent efficacy against non-small-cell lung cancer by targeting the CDK9\/STAT3 signalling pathway","volume":"124","author":"Yang","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbrc.2022.03.147_bib18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13046-019-1072-8","article-title":"Bazedoxifene as a novel GP130 inhibitor for Colon Cancer therapy","volume":"38","author":"Wei","year":"2019","journal-title":"J.\u00a0Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2022.03.147_bib19","doi-asserted-by":"crossref","first-page":"830","DOI":"10.7150\/thno.22012","article-title":"Drug repurposing screening identifies tioconazole as an ATG4 inhibitor that suppresses autophagy and sensitizes cancer cells to chemotherapy","volume":"8","author":"Liu","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.bbrc.2022.03.147_bib20","doi-asserted-by":"crossref","first-page":"5100","DOI":"10.1158\/1078-0432.CCR-15-0313","article-title":"Cyclin-dependent kinase inhibitor AT7519 as a potential drug for MYCN-dependent neuroblastoma","volume":"21","author":"Dolman","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2022.03.147_bib21","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1093\/annonc\/mdq734","article-title":"A\u00a0phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors","volume":"22","author":"Mahadevan","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbrc.2022.03.147_bib22","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1038\/bjc.2014.565","article-title":"A\u00a0Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177","volume":"111","author":"Chen","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbrc.2022.03.147_bib23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.semcancer.2019.09.022","article-title":"Repurposing of drugs as STAT3 inhibitors for cancer therapy, Semin","volume":"68","author":"Thilakasiri","year":"2021","journal-title":"Cancer Biol."},{"key":"10.1016\/j.bbrc.2022.03.147_bib24","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41568-018-0090-8","article-title":"Therapeutically exploiting STAT3 activity in cancer - using tissue repair as a road map","volume":"19","author":"Huynh","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2022.03.147_bib25","doi-asserted-by":"crossref","first-page":"37091","DOI":"10.1074\/jbc.M706458200","article-title":"The functional role of an interleukin 6-inducible CDK9.STAT3 complex in human gamma-fibrinogen gene expression","volume":"282","author":"Hou","year":"2007","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.bbrc.2022.03.147_bib26","doi-asserted-by":"crossref","first-page":"7391","DOI":"10.1038\/sj.onc.1207972","article-title":"Implication of BRG1 and cdk9 in the STAT3-mediated activation of the p21waf1 gene","volume":"23","author":"Giraud","year":"2004","journal-title":"Oncogene"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X22004922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X22004922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T12:17:23Z","timestamp":1757765843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X22004922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":26,"alternative-id":["S0006291X22004922"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2022.03.147","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AT7519 against lung cancer via the IL6\/STAT3 signaling pathway","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2022.03.147","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}